A phase 3, open-label, randomised study to compare the efficacy and safety of luspatercept (Ace-536) versus epoetin alfa for the treatment of anaemia due to Ipss-R very low, low or intermediate risk myelodysplastic syndromes (MDS) in ESA naive subjects who require red blood cell transfusions [ACE-536-MDS-002]

  • Kenealy, Melita (Primary Chief Investigator (PCI))
  • Baker, Emma (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date20/12/18 → 31/12/24

Keywords

  • Malignant Haematology
  • Anaemia
  • Clinical trial